Literature DB >> 11194891

Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains.

T Yamamoto1, M Kuroda, K Nishioka.   

Abstract

We have recently established a mouse model for scleroderma by repeated local bleomycin treatment. In this study, we compared the susceptibility to bleomycin in the development of dermal sclerosis among Balb/c, C3H/He, C57BL/6J, A/J, DBA/2, B10.BR, B10.A, and B10.D2 mouse strains. After either bleomycin or PBS treatment, skin from the injection site was histologically examined. Dermal sclerosis was induced by bleomycin treatment for 4 weeks in all of the strains examined. In particular, C3H/He, DBA/2, B10.D2 and B10.A mice developed intense dermal sclerosis characterized by deposition of homogeneous material in the dermis and thickened collagen bundles. Dermal thickness showed a more than twofold increase following bleomycin treatment, as compared with PBS treatment, except in C57BL/6J and DBA/2 mice. In A/J, C3H/He, B10.A, and B10.D2 mice, dermal thickness showed a more than 2.5-fold increase. Mast cell numbers in sclerotic skin were significantly greater than in PBS-treated skin in Balb/c and B10.A mice after 4 weeks of treatment. We also examined whether bleomycin treatment for 3 weeks could induce dermal sclerosis in C3H mice. Histological examination revealed that epidermal thickness as well as dermal sclerosis was increased in C3H mice following bleomycin treatment for 3 weeks. Increased hydroxyproline content as well as mRNA expression of alpha1(I) collagen, as determined by Northern blot analysis, were observed following bleomycin treatment. Taken together, we conclude that C3H/He and B10.A mouse strains are bleomycin-'susceptible', and these strains are considered to be a suitable experimental model of bleomycin-induced scleroderma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11194891     DOI: 10.1007/s004030000183

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  26 in total

1.  Mouse Models of Skin Fibrosis.

Authors:  Aleix Rius Rigau; Markus Luber; Jörg H W Distler
Journal:  Methods Mol Biol       Date:  2021

2.  Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma.

Authors:  M Kajii; C Suzuki; J Kashihara; F Kobayashi; Y Kubo; H Miyamoto; T Yuuki; T Yamamoto; T Nakae
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

Review 3.  Animal models in scleroderma.

Authors:  Stephen H Clark
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 4.  Molecular pathogenesis of skin fibrosis: insight from animal models.

Authors:  Gideon P Smith; Edwin S L Chan
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

5.  Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma.

Authors:  M Matsushita; T Yamamoto; K Nishioka
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

6.  Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.

Authors:  Takashi Taniguchi; Yoshihide Asano; Kaname Akamata; Shinji Noda; Takehiro Takahashi; Yohei Ichimura; Tetsuo Toyama; Maria Trojanowska; Shinichi Sato
Journal:  Arthritis Rheumatol       Date:  2015-02       Impact factor: 10.995

7.  Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studies.

Authors:  L Zhao; K Xiao; H Wang; Z Wang; L Sun; F Zhang; X Zhang; F Tang; W He
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

8.  Bone marrow-derived mesenchymal stem cell attenuates skin fibrosis development in mice.

Authors:  Yan Wu; Sha Huang; Jirigala Enhe; Kui Ma; Siming Yang; Tongzhu Sun; Xiaobing Fu
Journal:  Int Wound J       Date:  2013-02-15       Impact factor: 3.315

9.  CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma.

Authors:  Ayumi Yoshizaki; Yohei Iwata; Kazuhiro Komura; Fumihide Ogawa; Toshihide Hara; Eiji Muroi; Motoi Takenaka; Kazuhiro Shimizu; Minoru Hasegawa; Manabu Fujimoto; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

10.  The use of streptolysin o for the treatment of scars, adhesions and fibrosis: initial investigations using murine models of scleroderma.

Authors:  Stephen W Mamber; Vit Long; Ryan G Rhodes; Sunthorn Pond-Tor; Lyn R Wheeler; Kellie Fredericks; Brian Vanscoy; Jean-Frederic Sauniere; Remy Steinschneider; Jean-Claude Laurent; John McMichael
Journal:  Nonlinearity Biol Toxicol Med       Date:  2004-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.